Lactobacillus fermentum attenuates the alveolar bone loss in ligature-induced periodontitis in mice

Oral Dis. 2024 Jul;30(5):3328-3335. doi: 10.1111/odi.14739. Epub 2023 Sep 19.

Abstract

Objective: This study investigated the effects of Lactobacillus fermentum BELF11 on periodontitis in mice (LIP).

Methods: Sixty mice were randomly assigned to a control group (CTL), LIP/PBS group (LIP and PBS applied), or LIP/BELF11 group (LIP and L. fermentum BELF11 applied). For 14 days, PBS or L. fermentum BELF11 was applied twice daily to the mice in the LIP/PBS or LIP/BELF11 group, respectively. After 14 days, radiographic, histological, and pro-inflammatory cytokine assessments were conducted.

Results: The LIP/PBS and LIP/BELF11 groups demonstrated greater alveolar bone loss than the CTL group (p < 0.05). The LIP/BELF11 group showed significantly reduced alveolar bone loss on the mesial side compared to the LIP/PBS group. Histologically, the LIP/BELF11 group showed consistent patterns of connective tissue fiber arrangement, lower levels of inflammatory infiltration, less alveolar bone loss, and higher alveolar bone density than the LIP/PBS group, despite showing more signs of destruction than the CTL group. The LIP/BELF11 group also exhibited significantly lower levels of pro-inflammatory cytokines than the LIP/PBS group.

Conclusions: L. fermentum BELF11 inhibits alveolar bone loss and periodontitis progression by regulating pro-inflammatory cytokine production. These findings suggest that L. fermentum BELF11 may be a potential adjunctive therapy in periodontal treatment.

Keywords: X‐ray microtomography; alveolar bone loss; cytokine; periodontitis; probiotics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alveolar Bone Loss* / diagnostic imaging
  • Alveolar Bone Loss* / microbiology
  • Alveolar Bone Loss* / prevention & control
  • Animals
  • Cytokines / metabolism
  • Ligation
  • Limosilactobacillus fermentum*
  • Male
  • Mice
  • Periodontitis* / microbiology
  • Periodontitis* / pathology
  • Periodontitis* / therapy
  • Probiotics / therapeutic use
  • Random Allocation

Substances

  • Cytokines

Grants and funding